A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin.

Trial Profile

A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs TAK 448 (Primary) ; Leuprorelin
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2012 Planned end date changed from 1 Aug 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Actual patient number is 9 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top